Less than 5% of interventional cardiologists attempt left main bifurcation percutaneous coronary intervention stenting procedures because it is so complicated, according to estimates from Advanced Bifurcation Systems (ABS), a US medical device company with a patented bifurcation stenting platform.
The system was showcased at the Transcatheter Cardiovascular Therapeutics conference in San Diego, USA, earlier this year. The platform features the only modular self-aligning stent technology to evenly scaffold bifurcations. This may overcome the limitations of current bifurcation systems and reduce the incidence of restenosis and thrombosis associated with current procedures, thus potentially reducing the number of referrals for open-heart surgery.
ABS is hoping to obtain a CE Mark in Europe. Demonstrations of the system can be accessed at www.advancedbifurcation.com
Other news items in BJC Issue 4, 2018:
New heart failure nurse audit
European patient survey shows cancer-associated thrombosis
Preventing potentially fatal anaesthetic accidents
Peripheral arterial disease assessment training tool
News in brief